The past decade has witnessed unprecedented advances in renal transplantation propelled by novel and effective immunosuppression drugs.The introduction of mycophenolate mofetil(MMF), tacrolimus, cyclosporine microemulsion, sirolimus, a new generation of monoclonal antibodies(the anti-interleukin-2 receptor blockers, daclizumab and basiliximab), and the depleting polyclonal biological Thymoglobulin has provided transplant physicians with a wide choice in selecting effective immunosuppression regimens.The aim of this article is to review in brief current thoughts on new Immunosuppressive agents and their role in renal transplantation and graft survival.